Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance

20 Jul 2018

Abstract excerpt

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. The major challenge in the treatment of NSCLC patients is intrinsic or acquired resistance to chemotherapy. Molecular markers predicting the outcome of the patients are urgently needed. METHODS: Here,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Lung Cancer Treatments and Mutations
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30029672
DOI: 10.1186/s13073-018-0562-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistancePMID 30029672Read ↗

Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancerSemantic proximity Read ↗

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read ↗

Regulation of cisplatin resistance in lung cancer by epigenetic mechanismsSemantic proximity Read ↗

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Semantic proximity Read ↗

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity Read ↗

Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targetsSemantic proximity Read ↗

Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancerSemantic proximity Read ↗

Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment.Semantic proximity Read ↗

PiRNA-Hsap_1847317 may serve as a novel biomarker of PD-1 inhibitor resistance in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Genome-Wide Epigenomic Profiling of Primary Non-Small Cell Lung Cancer Reveals Specific and Recurrent DNA Methylation Alterations in Smoker Versus Never-Smoker PatientsSemantic proximity Read ↗

Plasma Exosomal DNA Methylation Profiles and Therapeutic Response in Non-Small Cell Lung CancerSemantic proximity Read ↗

Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.